Vali Musazadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vali Musazadeh has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Zeynab Kavyani
Student Research Committee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition & Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
13 shared publicationsAmir Hossein Faghfouri
Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran
11 shared publicationsMahsa Mahmoudinezhad
Student research committee, Urmia University of Medical Sciences, Urmia, Iran
8 shared publications- Farzad Shidfar
Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
7 shared publications - Parvin Dehghan
Nutrition Research Center, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
7 shared publications - Amir Hossein Faghfouri
Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran
6 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 23 (1)
Comparative efficacy of dietary patterns on glycemic and liver enzymes in metabolic dysfunction-associated steatotic liver disease: a network meta-analysis
Insulin resistance and hepatic dysfunction are strongly associated with metabolic dysfunction-associated steatotic liver disease (MASLD). Non-pharmacologic
- 13 July 2026
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 23 (1)
Open AccessComparative efficacy of dietary patterns on glycemic and liver enzymes in metabolic dysfunction-associated steatotic liver disease: a network meta-analysis
Insulin resistance and hepatic dysfunction are strongly associated with metabolic dysfunction-associated steatotic liver disease (MASLD). Non-pharmacologic
- Open Access
- 22 April 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (4) , e71715
Does Chlorella Supplementation Improve Adiposity, Metabolic Dysfunction, and Oxidative Stress in Individuals With Excess Weight? A Systematic Review and Meta‐Analysis
This systematic review and meta‐analysis was conducted to investigate the effects of Chlorella supplementation on cardiometabolic health indicators in individuals with overweight or obesity. A systematic search of PubMed, Scopus, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials was conducted up to November 2024. Eighteen studies published between 2012 and 2024 were included, involving a total of 717 participants. The duration of the trials ranged from 1 to 12 weeks, with daily Chlorella doses varying from 135 to 15,000 mg/day. Chlorella supplementation significantly reduced body fat percentage (WMD = −0.72%, 95% CI: −1.11 to −0.34), body mass index (WMD = −0.35 kg/m 2 , 95% CI: −0.55 to −0.14), weight (WMD = −1.41 kg; 95% CI: −2.19 to −0.64), Waist‐Hip Ratio (WMD = −0.01, 95% CI: −0.02 to −0.01), Homeostatic Model Assessment for Insulin Resistance (WMD = −0.16 units, 95% CI: −0.29 to −0.04), insulin levels (WMD = −1.00 μU/mL, 95% CI: −1.34 to −0.66), low‐density lipoprotein cholesterol (WMD = −5.73 mg/dL, 95% CI: −8.77 to −2.70), total cholesterol (WMD = −6.62 mg/dL, 95% CI: −10.18 to −3.05), triglycerides (WMD = −3.24 mg/dL, 95% CI: −6.25 to −0.23), alanine aminotransferase (WMD = −5.22 IU/L, 95% CI: −8.78 to −1.65), aspartate aminotransferase (WMD = −3.45 IU/L, 95% CI: −5.00 to −1.90), and leptin (WMD = −0.66 ng/mL, 95% CI: −1.24 to −0.08). Additionally, there were significant increases in catalase activity (WMD = 19.15 IU/g Hb, 95% CI: 0.44 to 37.85), and superoxide dismutase levels (WMD = 20.53 U/L, 95% CI: 15.03 to 26.02). Chlorella supplementation may benefit anthropometric and cardiometabolic outcomes in adults with overweight or obesity. However, the overall certainty of evidence was low to very low according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework, limiting confidence in these findings. Moreover, most included trials were conducted in Iran, which may restrict generalizability. Further high‐quality, well‐powered randomized trials in diverse populations are needed to confirm these effects.
- 22 April 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (4) , e71715
Open AccessDoes Chlorella Supplementation Improve Adiposity, Metabolic Dysfunction, and Oxidative Stress in Individuals With Excess Weight? A Systematic Review and Meta‐Analysis
This systematic review and meta‐analysis was conducted to investigate the effects of Chlorella supplementation on cardiometabolic health indicators in individuals with overweight or obesity. A systematic search of PubMed, Scopus, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials was conducted up to November 2024. Eighteen studies published between 2012 and 2024 were included, involving a total of 717 participants. The duration of the trials ranged from 1 to 12 weeks, with daily Chlorella doses varying from 135 to 15,000 mg/day. Chlorella supplementation significantly reduced body fat percentage (WMD = −0.72%, 95% CI: −1.11 to −0.34), body mass index (WMD = −0.35 kg/m 2 , 95% CI: −0.55 to −0.14), weight (WMD = −1.41 kg; 95% CI: −2.19 to −0.64), Waist‐Hip Ratio (WMD = −0.01, 95% CI: −0.02 to −0.01), Homeostatic Model Assessment for Insulin Resistance (WMD = −0.16 units, 95% CI: −0.29 to −0.04), insulin levels (WMD = −1.00 μU/mL, 95% CI: −1.34 to −0.66), low‐density lipoprotein cholesterol (WMD = −5.73 mg/dL, 95% CI: −8.77 to −2.70), total cholesterol (WMD = −6.62 mg/dL, 95% CI: −10.18 to −3.05), triglycerides (WMD = −3.24 mg/dL, 95% CI: −6.25 to −0.23), alanine aminotransferase (WMD = −5.22 IU/L, 95% CI: −8.78 to −1.65), aspartate aminotransferase (WMD = −3.45 IU/L, 95% CI: −5.00 to −1.90), and leptin (WMD = −0.66 ng/mL, 95% CI: −1.24 to −0.08). Additionally, there were significant increases in catalase activity (WMD = 19.15 IU/g Hb, 95% CI: 0.44 to 37.85), and superoxide dismutase levels (WMD = 20.53 U/L, 95% CI: 15.03 to 26.02). Chlorella supplementation may benefit anthropometric and cardiometabolic outcomes in adults with overweight or obesity. However, the overall certainty of evidence was low to very low according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework, limiting confidence in these findings. Moreover, most included trials were conducted in Iran, which may restrict generalizability. Further high‐quality, well‐powered randomized trials in diverse populations are needed to confirm these effects.
- Open Access
- 20 March 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70207
The Effect of Nigella sativa Supplementation on Cardiometabolic Health in Patients With Metabolic Diseases: A GRADE ‐Assessed Systematic Review and Meta‐Analysis
Background: Metabolic diseases, including type 2 diabetes and obesity, are primary drivers of cardiovascular disease (CVD) through the exacerbation of intermediate risk factors such as dysglycemia, hypertension, and central adiposity. Nigella sativa supplementation has been studied for its potential cardiometabolic benefits, but evidence from clinical trials remains inconsistent. In relation to this matter, a meta‐analysis was undertaken to present a more precise evaluation of the effect of N. sativa supplementation on cardiovascular risk factors in patients with metabolic diseases. Methods: The review was conducted in accordance with PRISMA guidelines. A random‐effects meta‐analysis was performed to calculate weighted mean differences (WMDs) with 95% confidence intervals. Heterogeneity was assessed using the I 2 statistic, and sensitivity analyses were conducted to examine the robustness of pooled estimates. Primary outcomes included obesity and glycemic indices, while blood pressure outcomes were considered secondary. Results: Meta‐analysis of 31 trials with 2145 participants revealed significant reductions in weight (WMD: −1.59 kg; 95% CI: −3.03 to −0.15), and BMI (WMD: −0.51 kg/m 2 ; 95% CI: −0.85 to −0.18), SBP (WMD = −3.25 mmHg; 95% CI: −4.44, −2.06), and DBP (WMD = −2.75 mmHg; 95% CI: −4.62, −0.89), FBS (WMD = −18.62 mg/dL; 95% CI: −23.30, −13.95), and HbA1c (WMD = −0.56; 95% CI: −0.79, −0.33) following N. sativa supplementation. Also, N. sativa had no effect on other indices such as WC, HC, WHR, HOMA‐IR, and insulin. Conclusion: This meta‐analysis suggests that N. sativa supplementation is associated with modest improvements in several cardiovascular risk factors. However, no significant effects were observed for measures of insulin resistance or central adiposity, and the findings should be interpreted cautiously given variability in study quality and outcomes. Further well‐designed trials are needed to clarify its clinical relevance.
- 20 March 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70207
Open AccessThe Effect of Nigella sativa Supplementation on Cardiometabolic Health in Patients With Metabolic Diseases: A GRADE ‐Assessed Systematic Review and Meta‐Analysis
Background: Metabolic diseases, including type 2 diabetes and obesity, are primary drivers of cardiovascular disease (CVD) through the exacerbation of intermediate risk factors such as dysglycemia, hypertension, and central adiposity. Nigella sativa supplementation has been studied for its potential cardiometabolic benefits, but evidence from clinical trials remains inconsistent. In relation to this matter, a meta‐analysis was undertaken to present a more precise evaluation of the effect of N. sativa supplementation on cardiovascular risk factors in patients with metabolic diseases. Methods: The review was conducted in accordance with PRISMA guidelines. A random‐effects meta‐analysis was performed to calculate weighted mean differences (WMDs) with 95% confidence intervals. Heterogeneity was assessed using the I 2 statistic, and sensitivity analyses were conducted to examine the robustness of pooled estimates. Primary outcomes included obesity and glycemic indices, while blood pressure outcomes were considered secondary. Results: Meta‐analysis of 31 trials with 2145 participants revealed significant reductions in weight (WMD: −1.59 kg; 95% CI: −3.03 to −0.15), and BMI (WMD: −0.51 kg/m 2 ; 95% CI: −0.85 to −0.18), SBP (WMD = −3.25 mmHg; 95% CI: −4.44, −2.06), and DBP (WMD = −2.75 mmHg; 95% CI: −4.62, −0.89), FBS (WMD = −18.62 mg/dL; 95% CI: −23.30, −13.95), and HbA1c (WMD = −0.56; 95% CI: −0.79, −0.33) following N. sativa supplementation. Also, N. sativa had no effect on other indices such as WC, HC, WHR, HOMA‐IR, and insulin. Conclusion: This meta‐analysis suggests that N. sativa supplementation is associated with modest improvements in several cardiovascular risk factors. However, no significant effects were observed for measures of insulin resistance or central adiposity, and the findings should be interpreted cautiously given variability in study quality and outcomes. Further well‐designed trials are needed to clarify its clinical relevance.
- Open Access
- 20 March 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70182
Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta‐Analyses of Randomised Controlled Trials
Background: Several meta‐analyses suggest that Coenzyme Q10 (CoQ10) supplementation is associated with glycemic control; however, findings about fasting blood glucose (FBG) and haemoglobin A1c (HbA1c) remain inconsistent across studies. Accordingly, this study aimed to synthesise the results to present a firm conclusion in relation to the efficacy of CoQ10 on glycemic control. Methods: A systematic search was conducted to find meta‐analyses of randomised controlled trials using PubMed, Scopus, Web of Science and the Cochrane Database of Systematic Reviews from inception to March 6, 2025. Also, the methodological quality of included studies was evaluated using the AMSTAR2 tool. Results: In total, eight meta‐analyses were included in this umbrella systematic review and meta‐analysis. Pooled analysis using standardized mean difference analysis demonstrated that CoQ10 is associated with decreased FBG. While it didn't exert any significant changes on the HbA1c, HOMA‐IR, and insulin levels. In addition, the combined effect of CoQ10 using weighted mean difference analysis revealed that CoQ10 is able to decrease the FBG (5.04 mg/dL), HbA1c (0.17%), HOMA‐IR (0.72), and insulin (1.32 μIU/mL) levels significantly. Conclusion: The present study suggests that CoQ10 supplementation may have a moderate beneficial effect on glycemic control in diabetic patients, though findings differ depending on analytic approach.
- 20 March 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70182
Open AccessEffects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta‐Analyses of Randomised Controlled Trials
Background: Several meta‐analyses suggest that Coenzyme Q10 (CoQ10) supplementation is associated with glycemic control; however, findings about fasting blood glucose (FBG) and haemoglobin A1c (HbA1c) remain inconsistent across studies. Accordingly, this study aimed to synthesise the results to present a firm conclusion in relation to the efficacy of CoQ10 on glycemic control. Methods: A systematic search was conducted to find meta‐analyses of randomised controlled trials using PubMed, Scopus, Web of Science and the Cochrane Database of Systematic Reviews from inception to March 6, 2025. Also, the methodological quality of included studies was evaluated using the AMSTAR2 tool. Results: In total, eight meta‐analyses were included in this umbrella systematic review and meta‐analysis. Pooled analysis using standardized mean difference analysis demonstrated that CoQ10 is associated with decreased FBG. While it didn't exert any significant changes on the HbA1c, HOMA‐IR, and insulin levels. In addition, the combined effect of CoQ10 using weighted mean difference analysis revealed that CoQ10 is able to decrease the FBG (5.04 mg/dL), HbA1c (0.17%), HOMA‐IR (0.72), and insulin (1.32 μIU/mL) levels significantly. Conclusion: The present study suggests that CoQ10 supplementation may have a moderate beneficial effect on glycemic control in diabetic patients, though findings differ depending on analytic approach.
- Open Access
- 20 March 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70171
Does Walnut Supplementation Have Favourable Effect Apolipoprotein A, B and Blood Pressure? A Systematic Review, Meta‐Analysis and Meta‐Evidence of Randomised Clinical Trials
Backgrounds: Many randomised controlled trials (RCTs) have revealed the benefits of walnut on apolipoproteins and blood pressure, but the results are inconclusive. This meta‐analysis of RCTs aimed to assess the effects of walnut on Apolipoprotein B (ApoB), apolipoprotein A1 (ApoA1) and blood pressure. Methods: A systematic review of PubMed, Scopus, Web of Science, Cochrane and Embase databases was conducted, and the search time frame was from the establishment of the database up to January of 2025. A random effects model was applied to estimate weighted mean differences (WMDs) and 95% confidence intervals (CIs). Results: Twenty‐five RCTs comprising 26 intervention arms with 2155 patients were included. Walnut significantly decreased ApoB (WMD = −0.06; 95% CI: −0.10, −0.01, p = 0.002), but did not affect ApoA1 (WMD = −0.50; 95% CI: −1.34, 0.33, p = 0.249), systolic blood pressure (SBP) (WMD = −1.20; 95% CI: −4.02, 1.61, p = 0.401) and diastolic blood pressure (DBP) (WMD = −0.44; 95% CI: −2.55, 1.67, p = 0.682). Conclusion: Walnut intake was associated with reduced ApoB levels, with no significant effects observed on ApoA1, SBP, or DBP. Future research involving large‐scale, international RCTs is essential to validate its therapeutic potential further.
- 20 March 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70171
Open AccessDoes Walnut Supplementation Have Favourable Effect Apolipoprotein A, B and Blood Pressure? A Systematic Review, Meta‐Analysis and Meta‐Evidence of Randomised Clinical Trials
Backgrounds: Many randomised controlled trials (RCTs) have revealed the benefits of walnut on apolipoproteins and blood pressure, but the results are inconclusive. This meta‐analysis of RCTs aimed to assess the effects of walnut on Apolipoprotein B (ApoB), apolipoprotein A1 (ApoA1) and blood pressure. Methods: A systematic review of PubMed, Scopus, Web of Science, Cochrane and Embase databases was conducted, and the search time frame was from the establishment of the database up to January of 2025. A random effects model was applied to estimate weighted mean differences (WMDs) and 95% confidence intervals (CIs). Results: Twenty‐five RCTs comprising 26 intervention arms with 2155 patients were included. Walnut significantly decreased ApoB (WMD = −0.06; 95% CI: −0.10, −0.01, p = 0.002), but did not affect ApoA1 (WMD = −0.50; 95% CI: −1.34, 0.33, p = 0.249), systolic blood pressure (SBP) (WMD = −1.20; 95% CI: −4.02, 1.61, p = 0.401) and diastolic blood pressure (DBP) (WMD = −0.44; 95% CI: −2.55, 1.67, p = 0.682). Conclusion: Walnut intake was associated with reduced ApoB levels, with no significant effects observed on ApoA1, SBP, or DBP. Future research involving large‐scale, international RCTs is essential to validate its therapeutic potential further.
- Open Access
- 25 November 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 952
Can vitamin D supplementation affect cardiometabolic factors in children and adolescence with overweight and obesity? A grade-assessed systematic review and meta-analysis of randomized controlled trials
Vitamin D have been proposed as a supplement to improve cardiometabolic risk factors in obese/overweight children and adolescents. However, findings eviden
- 25 November 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 952
Open AccessCan vitamin D supplementation affect cardiometabolic factors in children and adolescence with overweight and obesity? A grade-assessed systematic review and meta-analysis of randomized controlled trials
Vitamin D have been proposed as a supplement to improve cardiometabolic risk factors in obese/overweight children and adolescents. However, findings eviden
- 20 November 2025
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 19 (10) , 103328
Artichoke and cardiometabolic health: A systematic and meta-analytic synthesis of current evidence
- 20 November 2025
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 19 (10) , 103328
Artichoke and cardiometabolic health: A systematic and meta-analytic synthesis of current evidence
- Open Access
- 9 September 2025
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 134 (7) , 529-577
The effect of ginseng supplementation on CVD risk factors: a comprehensive systematic review and dose–response meta-analysis
Although numerous clinical studies suggest that ginseng supplementation may benefit CVD risk factors, results remain inconclusive. This systematic review and meta-analysis evaluated the effects of ginseng supplementation on CVD-related risk factors. Relevant studies were identified through electronic searches in Embase, Web of Science, Scopus, PubMed and CENTRAL up to August 2024. Statistical analyses, including a random effects model, meta-regression and non-linear modelling, were used to assess heterogeneity, dose–response relationships and the overall effects of ginseng supplementation. A total of 70 studies, published between 1998 and 2024 and involving 4506 participants, were included. Ginseng supplementation significantly affected several biochemical markers, including high-sensitivity C-reactive protein (standardised mean difference (SMD): −0·23; 95 % CI: −0·38, −0·08; P = 0·002), gamma-glutamyl transferase (SMD: −0·20; 95 % CI: −0·36, −0·04; P = 0·015), glutathione reductase (SMD: 0·90; 95 % CI: 0·38, 1·42; P = 0·001), reactive oxygen species (SMD: −0·94; 95 % CI: −1·27, −0·60; P < 0·001) and superoxide dismutase (SMD: 0·48; 95 % CI: 0·10, 0·87; P = 0·014). Meta-regression analysis showed significant linear associations between ginseng dosage and Homeostatic Model Assessment for Insulin Resistance ( P = 0·044) and between supplementation duration and malondialdehyde ( P = 0·007). Dose–response analysis revealed significant associations between ginseng dose and fasting blood glucose ( P < 0·001), high-sensitivity C-reactive protein ( P = 0·043), IL-6 ( P = 0·041), diastolic blood pressure ( P = 0·022), IL-10 ( P = 0·048), fasting insulin ( P = 0·012) and total protein ( P = 0·010). Supplementation duration was positively associated with malondialdehyde levels ( P = 0·008). Ginseng supplementation was associated with improvements in inflammatory markers, liver function and oxidative stress parameters. No significant effects were observed on anthropometric indices, blood pressure, glycaemic profile, lipid profile, adipokines or heart rate.
- 9 September 2025
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 134 (7) , 529-577
Open AccessThe effect of ginseng supplementation on CVD risk factors: a comprehensive systematic review and dose–response meta-analysis
Although numerous clinical studies suggest that ginseng supplementation may benefit CVD risk factors, results remain inconclusive. This systematic review and meta-analysis evaluated the effects of ginseng supplementation on CVD-related risk factors. Relevant studies were identified through electronic searches in Embase, Web of Science, Scopus, PubMed and CENTRAL up to August 2024. Statistical analyses, including a random effects model, meta-regression and non-linear modelling, were used to assess heterogeneity, dose–response relationships and the overall effects of ginseng supplementation. A total of 70 studies, published between 1998 and 2024 and involving 4506 participants, were included. Ginseng supplementation significantly affected several biochemical markers, including high-sensitivity C-reactive protein (standardised mean difference (SMD): −0·23; 95 % CI: −0·38, −0·08; P = 0·002), gamma-glutamyl transferase (SMD: −0·20; 95 % CI: −0·36, −0·04; P = 0·015), glutathione reductase (SMD: 0·90; 95 % CI: 0·38, 1·42; P = 0·001), reactive oxygen species (SMD: −0·94; 95 % CI: −1·27, −0·60; P < 0·001) and superoxide dismutase (SMD: 0·48; 95 % CI: 0·10, 0·87; P = 0·014). Meta-regression analysis showed significant linear associations between ginseng dosage and Homeostatic Model Assessment for Insulin Resistance ( P = 0·044) and between supplementation duration and malondialdehyde ( P = 0·007). Dose–response analysis revealed significant associations between ginseng dose and fasting blood glucose ( P < 0·001), high-sensitivity C-reactive protein ( P = 0·043), IL-6 ( P = 0·041), diastolic blood pressure ( P = 0·022), IL-10 ( P = 0·048), fasting insulin ( P = 0·012) and total protein ( P = 0·010). Supplementation duration was positively associated with malondialdehyde levels ( P = 0·008). Ginseng supplementation was associated with improvements in inflammatory markers, liver function and oxidative stress parameters. No significant effects were observed on anthropometric indices, blood pressure, glycaemic profile, lipid profile, adipokines or heart rate.
- Open Access
- 24 July 2025
- Published by Elsevier in Pharmacological Research
- Vol. 219, 107882
Does Nigella sativa supplementation improve cardiovascular disease risk factors? A comprehensive GRADE-assessed systematic review and dose-response meta-analysis of 82 randomized controlled trials
- 24 July 2025
- Published by Elsevier in Pharmacological Research
- Vol. 219, 107882
Open AccessDoes Nigella sativa supplementation improve cardiovascular disease risk factors? A comprehensive GRADE-assessed systematic review and dose-response meta-analysis of 82 randomized controlled trials